Phase 2 Study of Acalabrutinib Window Prior to Frontline Therapy in Untreated Aggressive B-Cell Lymphoma: Preliminary Results and Correlatives of Response to Acalabrutinib Roschewski, M., Phelan, J. D., Pittaluga, S., Melani, C., Lakhotia, R., Chabon, J. J., Muppidi, J. R., Lurain, K. A., Simard, J., Pradhan, A., Hillsman, A., Rilko, M., Steinberg, S. M., Wright, G. W., Huang, D., Yang, Y., Lionakis, M. S., Bagaev, A., Postovalova, E., Meerson, M., Kudryashova, O., Kotlov, N., Fowler, N. H., Kurtz, D. M., Alizadeh, A. A., Jaffe, E. S., Staudt, L. M., Wilson, W. H. AMER SOC HEMATOLOGY. 2021

View details for DOI 10.1182/blood-2021-145228

View details for Web of Science ID 000736398802066